Indeed, several c‐Abl inhibitors including imatinib,29 nilotinib,61, 67, 68 bafetinib,69 radotinib,61 and the novel inhibitors in clinical development vodobatinib/SCC‐138/K070670 and IkT‐14800971, 72 have all demonstrated that c‐Abl inhibition can act prophylactically and/or therapeutically to counter neurodegeneration in animal models of PD. Here, ABL1 is linked to Parkinson disease.